Trexquant Investment LP cut its stake in shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) by 27.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,474 shares of the biopharmaceutical company’s stock after selling 10,003 shares during the quarter. Trexquant Investment LP’s holdings in Dicerna Pharmaceuticals were worth $476,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of DRNA. Macquarie Group Ltd. acquired a new stake in Dicerna Pharmaceuticals in the second quarter valued at $62,000. Pacer Advisors Inc. acquired a new stake in Dicerna Pharmaceuticals in the third quarter valued at $55,000. Nisa Investment Advisors LLC lifted its holdings in Dicerna Pharmaceuticals by 303.2% in the third quarter. Nisa Investment Advisors LLC now owns 3,125 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 2,350 shares during the period. US Bancorp DE lifted its holdings in Dicerna Pharmaceuticals by 35.6% in the second quarter. US Bancorp DE now owns 4,035 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 1,060 shares during the period. Finally, Advisors Asset Management Inc. acquired a new stake in Dicerna Pharmaceuticals in the second quarter valued at $119,000. 74.95% of the stock is owned by hedge funds and other institutional investors.
Dicerna Pharmaceuticals stock opened at $22.83 on Friday. The stock has a market cap of $1.71 billion, a PE ratio of -14.18 and a beta of 1.35. The stock has a 50-day moving average price of $20.79 and a 200 day moving average price of $21.17. Dicerna Pharmaceuticals, Inc. has a 52 week low of $11.75 and a 52 week high of $27.68.
A number of equities research analysts have commented on the company. Zacks Investment Research raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, November 6th. SVB Leerink raised their price target on Dicerna Pharmaceuticals from $43.00 to $46.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. HC Wainwright raised their price target on Dicerna Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, August 7th. BidaskClub upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 29th. Finally, B. Riley restated a “buy” rating and issued a $30.00 price target on shares of Dicerna Pharmaceuticals in a research report on Monday, August 10th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Dicerna Pharmaceuticals has an average rating of “Buy” and an average price target of $34.27.
In other Dicerna Pharmaceuticals news, CEO Douglas Fambrough purchased 10,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was bought at an average price of $18.06 per share, for a total transaction of $180,600.00. Following the acquisition, the chief executive officer now directly owns 22,300 shares of the company’s stock, valued at $402,738. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Regina M. Paglia sold 30,000 shares of Dicerna Pharmaceuticals stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $22.75, for a total value of $682,500.00. Following the completion of the sale, the insider now owns 30,000 shares of the company’s stock, valued at approximately $682,500. The disclosure for this sale can be found here. Insiders sold a total of 67,635 shares of company stock valued at $1,465,887 in the last 90 days. 11.30% of the stock is owned by company insiders.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases.
Want to see what other hedge funds are holding DRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.